These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 26562694

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. How to best measure the effectiveness of male human papillomavirus vaccine programmes?
    Garland SM, Molesworth EG, Machalek DA, Cornall AM, Tabrizi SN.
    Clin Microbiol Infect; 2015 Sep; 21(9):834-41. PubMed ID: 26055415
    [Abstract] [Full Text] [Related]

  • 26. Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines.
    Dunne EF, Friedman A, Datta SD, Markowitz LE, Workowski KA.
    Clin Infect Dis; 2011 Dec; 53 Suppl 3():S143-52. PubMed ID: 22080267
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
    Steben M, Ouhoummane N, Rodier C, Sinyavskaya L, Brassard P.
    J Med Virol; 2018 Mar; 90(3):592-598. PubMed ID: 28980715
    [Abstract] [Full Text] [Related]

  • 31. Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States.
    Hariri S, Schuler MS, Naleway AL, Daley MF, Weinmann S, Crane B, Newcomer SR, Tolsma D, Markowitz LE.
    Am J Epidemiol; 2018 Feb 01; 187(2):298-305. PubMed ID: 28641366
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls.
    Blomberg M, Dehlendorff C, Sand C, Kjaer SK.
    Clin Infect Dis; 2015 Sep 01; 61(5):676-82. PubMed ID: 25944340
    [Abstract] [Full Text] [Related]

  • 35. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment.
    Guerra FM, Rosella LC, Dunn S, Wilson SE, Chen C, Deeks SL.
    Vaccine; 2016 Sep 07; 34(39):4678-4683. PubMed ID: 27527815
    [Abstract] [Full Text] [Related]

  • 36. Human papillomavirus vaccination in males.
    Giuliano AR.
    Gynecol Oncol; 2007 Nov 07; 107(2 Suppl 1):S24-6. PubMed ID: 17938015
    [Abstract] [Full Text] [Related]

  • 37. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
    Dahlstrom KR, Fu S, Chan W, Shelal Z, Ramondetta LM, Lairson DR.
    Pharmacoeconomics; 2018 Nov 07; 36(11):1355-1365. PubMed ID: 30019118
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Acceptability of human papillomavirus vaccine for males: a review of the literature.
    Liddon N, Hood J, Wynn BA, Markowitz LE.
    J Adolesc Health; 2010 Feb 07; 46(2):113-23. PubMed ID: 20113917
    [Abstract] [Full Text] [Related]

  • 40. HPV vaccine acceptance among adolescent males and their parents in two suburban pediatric practices.
    Khurana S, Sipsma HL, Caskey RN.
    Vaccine; 2015 Mar 24; 33(13):1620-4. PubMed ID: 25659275
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.